{"id":"ct-p13","safety":{"commonSideEffects":[{"rate":null,"effect":"Infections (including serious infections)"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Tuberculosis reactivation"}]},"_chembl":{"chemblId":"CHEMBL3979339","moleculeType":"Small molecule","molecularWeight":"361.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CT-P13 is a monoclonal antibody that targets and neutralizes TNF-α, a key pro-inflammatory cytokine. By blocking TNF-α, it suppresses the inflammatory cascade involved in autoimmune and inflammatory diseases. This mechanism is identical to the reference biologic infliximab, making CT-P13 a biosimilar with comparable efficacy and safety.","oneSentence":"CT-P13 is a biosimilar of infliximab that binds to tumor necrosis factor-alpha (TNF-α) to reduce inflammatory signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:28.706Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT03819296","phase":"PHASE1","title":"Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-21","conditions":"Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8","enrollment":800},{"nctId":"NCT06381518","phase":"NA","title":"Switching From Intravenous to Subcutaneous Infliximab in Adult Patients With Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Zuyderland Medisch Centrum","startDate":"2024-03-12","conditions":"IBD, Infliximab, Crohn Disease","enrollment":38},{"nctId":"NCT04407247","phase":"PHASE1, PHASE2","title":"Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-09","conditions":"Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm","enrollment":47},{"nctId":"NCT04898231","phase":"PHASE2, PHASE3","title":"MIS-C Comparative Effectiveness Study","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2020-12-22","conditions":"Multisystem Inflammatory Syndrome-Children","enrollment":73},{"nctId":"NCT07120152","phase":"","title":"A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease","status":"NOT_YET_RECRUITING","sponsor":"Erwin Dreesen","startDate":"2025-09-01","conditions":"IBD - Inflammatory Bowel Disease, RA - Rheumatoid Arthritis","enrollment":439},{"nctId":"NCT06738719","phase":"PHASE3","title":"A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celltrion","startDate":"2025-01-03","conditions":"Moderately to Severely Active Rheumatoid Arthritis","enrollment":192},{"nctId":"NCT03011268","phase":"NA","title":"Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not?","status":"COMPLETED","sponsor":"Helse Møre og Romsdal HF","startDate":"2017-06-09","conditions":"Colitis,Ulcerative","enrollment":174},{"nctId":"NCT03681652","phase":"","title":"Post-Operative Crohn's Disease Outcome in Children","status":"RECRUITING","sponsor":"Schneider Children's Medical Center, Israel","startDate":"2019-02-11","conditions":"Crohn Disease","enrollment":100},{"nctId":"NCT05722353","phase":"NA","title":"IBD Disease Course of Infliximab-naïve IBD Patients Treated With Subcutaneous Infliximab CT-P13 Remsima®","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-02-13","conditions":"Inflammatory Bowel Diseases","enrollment":120},{"nctId":"NCT03937609","phase":"PHASE4","title":"TITRATE (inducTIon for acuTe ulceRATivE Colitis)","status":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2019-09-04","conditions":"Colitis, Ulcerative","enrollment":50},{"nctId":"NCT04646187","phase":"PHASE4","title":"De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease","status":"ENROLLING_BY_INVITATION","sponsor":"University Medical Center Groningen","startDate":"2021-03-11","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative","enrollment":148},{"nctId":"NCT06059989","phase":"PHASE3","title":"InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-11-25","conditions":"Inflammatory Disease, Disease Crohn, Bowel Disease","enrollment":158},{"nctId":"NCT06591273","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Services Institute of Medical Sciences, Pakistan","startDate":"2023-11-06","conditions":"Moderate to Severe Chronic Plaque Psoriasis","enrollment":104},{"nctId":"NCT05866614","phase":"","title":"A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps","status":"RECRUITING","sponsor":"Celltrion","startDate":"2023-01-13","conditions":"Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis","enrollment":864},{"nctId":"NCT06274294","phase":"PHASE3","title":"Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients With Active CD or UC","status":"UNKNOWN","sponsor":"CMC Ambroise Paré","startDate":"2024-07-10","conditions":"Inflammatory Bowel Diseases","enrollment":130},{"nctId":"NCT06051253","phase":"PHASE4","title":"TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2023-11-01","conditions":"Crohn Disease, Infliximab, Perianal Fistula Due to Crohn's Disease","enrollment":86},{"nctId":"NCT04990258","phase":"","title":"A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC","status":"UNKNOWN","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2021-09-06","conditions":"Inflammatory Bowel Diseases","enrollment":444},{"nctId":"NCT05663268","phase":"EARLY_PHASE1","title":"Efficacy and Safety of Infliximab Biosimilar in the Treatment of Resistant Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"Services Institute of Medical Sciences, Pakistan","startDate":"2022-10-01","conditions":"Hidradenitis Suppurativa","enrollment":37},{"nctId":"NCT03945019","phase":"PHASE3","title":"CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)","status":"COMPLETED","sponsor":"Celltrion","startDate":"2019-10-28","conditions":"Crohn's Disease","enrollment":396},{"nctId":"NCT04205643","phase":"PHASE3","title":"CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)","status":"COMPLETED","sponsor":"Celltrion","startDate":"2020-09-01","conditions":"Ulcerative Colitis","enrollment":548},{"nctId":"NCT06043752","phase":"PHASE4","title":"Efficacy and Safety of Infliximab Biosimilar Remsima in Psoriasis","status":"COMPLETED","sponsor":"Ghurki Trust and Teaching Hospital","startDate":"2022-03-10","conditions":"Psoriasis","enrollment":51},{"nctId":"NCT05719389","phase":"","title":"EFFICACY AND SAFETY OF S.C. INFLIXIMAB IN PATIENTS SWITCHED FROM I.V. FORMULATION OF INFLIXIMAB","status":"UNKNOWN","sponsor":"IRCCS San Raffaele","startDate":"2022-09-14","conditions":"Inflammatory Bowel Diseases, Rheumatologic Disease","enrollment":250},{"nctId":"NCT05584228","phase":"NA","title":"Medical Treatment Versus Surgery in Stricturing Small Bowel Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2023-04-01","conditions":"Crohn Disease","enrollment":150},{"nctId":"NCT05072782","phase":"PHASE4","title":"Management of Moderate POstoperative Recurrence in Crohn's Disease: a randoMizEd contROLled Trial of Therapeutic Escalation, the POMEROL Trial. (POMEROL)","status":"UNKNOWN","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2021-12-21","conditions":"Crohn Disease","enrollment":360},{"nctId":"NCT02326155","phase":"","title":"To Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)","status":"TERMINATED","sponsor":"Celltrion","startDate":"2014-12-08","conditions":"Crohn's Disease, Ulcerative Colitis","enrollment":470},{"nctId":"NCT05164198","phase":"PHASE4","title":"REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2022-01-15","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis","enrollment":448},{"nctId":"NCT05051137","phase":"","title":"Real-World Emulation of the SWEFOT Trial","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2006-01-12","conditions":"Rheumatoid Arthritis","enrollment":509},{"nctId":"NCT03707535","phase":"PHASE3","title":"To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2018-11-12","conditions":"Rheumatoid Arthritis","enrollment":270},{"nctId":"NCT03452501","phase":"","title":"Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients","status":"COMPLETED","sponsor":"Hikma Pharmaceuticals LLC","startDate":"2018-08-26","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Fistulizing Crohn's Disease","enrollment":157},{"nctId":"NCT02846961","phase":"","title":"Anti CT-P13 Antibody in Moderate to Severe Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Kyungpook National University Hospital","startDate":"2016-07","conditions":"Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease","enrollment":280},{"nctId":"NCT02883452","phase":"PHASE1","title":"A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2016-09-29","conditions":"Crohn's Disease, Ulcerative Colitis (Part 2 Only)","enrollment":181},{"nctId":"NCT03147248","phase":"PHASE3","title":"A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA","status":"COMPLETED","sponsor":"Celltrion","startDate":"2016-09-12","conditions":"Rheumatoid Arthritis","enrollment":407},{"nctId":"NCT03348046","phase":"","title":"Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan","status":"COMPLETED","sponsor":"Hikma Pharmaceuticals LLC","startDate":"2017-03-23","conditions":"Rheumatoid Arthritis","enrollment":22},{"nctId":"NCT02539368","phase":"","title":"Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-04-22","conditions":"Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn's Disease","enrollment":2565},{"nctId":"NCT02605642","phase":"","title":"Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-09-10","conditions":"Rheumatoid Diseases, Rheumatoid Arthritis, Ankylosing Spondylitis","enrollment":351},{"nctId":"NCT03016260","phase":"","title":"RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"TcLand Expression S.A.","startDate":"2016-12","conditions":"RheumatoId Arthritis","enrollment":250},{"nctId":"NCT03446976","phase":"PHASE1","title":"CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects","status":"COMPLETED","sponsor":"Celltrion","startDate":"2018-02-21","conditions":"Health, Subjective","enrollment":218},{"nctId":"NCT03108326","phase":"","title":"Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease","status":"UNKNOWN","sponsor":"Ced Service GmbH","startDate":"2017-04-15","conditions":"Crohn Disease","enrollment":900},{"nctId":"NCT02096861","phase":"PHASE3","title":"Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease","status":"COMPLETED","sponsor":"Celltrion","startDate":"2014-09-19","conditions":"Crohn's Disease","enrollment":220},{"nctId":"NCT02148640","phase":"PHASE4","title":"The NOR-SWITCH Study","status":"COMPLETED","sponsor":"Diakonhjemmet Hospital","startDate":"2014-10","conditions":"Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis","enrollment":482},{"nctId":"NCT01571219","phase":"PHASE3","title":"An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1","status":"COMPLETED","sponsor":"Celltrion","startDate":"2012-03","conditions":"Rheumatoid Arthritis","enrollment":302},{"nctId":"NCT02457585","phase":"PHASE2","title":"Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2015-03","conditions":"Takayasu's Arteritis","enrollment":11},{"nctId":"NCT01571206","phase":"PHASE1","title":"An Extension Study to Demonstrate the Equivalence of Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1","status":"COMPLETED","sponsor":"Celltrion","startDate":"2012-03","conditions":"Ankylosing Spondylitis","enrollment":174},{"nctId":"NCT01217086","phase":"PHASE3","title":"Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)","status":"COMPLETED","sponsor":"Celltrion","startDate":"2010-10","conditions":"Rheumatoid Arthritis","enrollment":617},{"nctId":"NCT01220518","phase":"PHASE1","title":"Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)","status":"COMPLETED","sponsor":"Celltrion","startDate":"2010-10","conditions":"Ankylosing Spondylitis","enrollment":257},{"nctId":"NCT00005802","phase":"PHASE1, PHASE2","title":"Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"1999-06","conditions":"Leukemia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":360,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Infliximab","Inflectra","Remsima"],"phase":"phase_3","status":"active","brandName":"CT-P13","genericName":"CT-P13","companyName":"CMC Ambroise Paré","companyId":"cmc-ambroise-par","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CT-P13 is a biosimilar of infliximab that binds to tumor necrosis factor-alpha (TNF-α) to reduce inflammatory signaling. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":6,"withResults":5},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}